Effects of propentofylline on adenosine receptor activity in Chinese hamster ovary cell lines transfected with human A1, A2A, or A2B receptors and a luciferase reporter gene.
Identifieur interne : 000019 ( Ncbi/Merge ); précédent : 000018; suivant : 000020Effects of propentofylline on adenosine receptor activity in Chinese hamster ovary cell lines transfected with human A1, A2A, or A2B receptors and a luciferase reporter gene.
Auteurs : S L Borgland [Canada] ; M. Casta N ; W. Spevak ; F E ParkinsonSource :
- Canadian journal of physiology and pharmacology [ 0008-4212 ] ; 1998.
English descriptors
- KwdEn :
- Adenosine (pharmacology), Animals, CHO Cells, Colforsin (pharmacology), Cricetinae, Genes, Reporter (drug effects), Humans, Luciferases (biosynthesis), Luciferases (drug effects), Luciferases (genetics), Neuroprotective Agents (pharmacology), Purinergic P1 Receptor Antagonists, Receptor, Adenosine A2A, Receptor, Adenosine A2B, Receptors, Purinergic P1 (drug effects), Receptors, Purinergic P1 (genetics), Transfection, Xanthines (pharmacology).
- MESH :
- chemical , biosynthesis : Luciferases.
- chemical , drug effects : Luciferases, Receptors, Purinergic P1.
- chemical , genetics : Luciferases, Receptors, Purinergic P1.
- chemical , pharmacology : Adenosine, Colforsin, Neuroprotective Agents, Xanthines.
- drug effects : Genes, Reporter.
- Animals, CHO Cells, Cricetinae, Humans, Purinergic P1 Receptor Antagonists, Receptor, Adenosine A2A, Receptor, Adenosine A2B, Transfection.
Abstract
Propentofylline is neuroprotective in vivo, but its mechanism of action is not completely understood. Previously, propentofylline was shown to block adenosine transport processes, to inhibit three adenosine receptor subtypes, and to inhibit cAMP phosphodiesterase. We tested the effect of propentofylline on adenosine receptor function in Chinese hamster ovary (CHO) cells transfected with human adenosine A1, A2A, or A2B receptors and a luciferase reporter gene under control of a promoter sequence containing several copies of the cAMP response element. We investigated the concentration-dependent inhibitory effects of propentofylline on cAMP phosphodiesterase, adenosine transport processes, and adenosine A1, A2A, and A2B receptors. At concentrations > or = 1 mM, propentofylline increased luciferase activity probably as a result of inhibition of cAMP phosphodiesterase. Inhibition of [3H]adenosine uptake by propentofylline was concentration dependent, with IC50 values of 37-39 microM for the three cell types. Agonist-activated adenosine A1 receptors were antagonized by 100 microM propentofylline, but inhibition of agonist-stimulated A2A or A2B receptors was not observed. In contrast, A1 and A2A receptor mediated effects of adenosine were enhanced by propentofylline at concentrations of 1 and 100 microM, respectively. These data indicate that the net effects of propentofylline in vivo will be dependent on the concentrations of propentofylline and adenosine available and on the subtypes of adenosine receptors, phosphodiesterases, and nucleoside transporters present.
PubMed: 10326835
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001740
- to stream PubMed, to step Curation: 001740
- to stream PubMed, to step Checkpoint: 001740
Links to Exploration step
pubmed:10326835Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of propentofylline on adenosine receptor activity in Chinese hamster ovary cell lines transfected with human A1, A2A, or A2B receptors and a luciferase reporter gene.</title><author><name sortKey="Borgland, S L" sort="Borgland, S L" uniqKey="Borgland S" first="S L" last="Borgland">S L Borgland</name><affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacology and Therapeutics, The University of Manitoba, Winnipeg, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology and Therapeutics, The University of Manitoba, Winnipeg</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author><author><name sortKey="Casta N, M" sort="Casta N, M" uniqKey="Casta N M" first="M" last="Casta N">M. Casta N</name></author><author><name sortKey="Spevak, W" sort="Spevak, W" uniqKey="Spevak W" first="W" last="Spevak">W. Spevak</name></author><author><name sortKey="Parkinson, F E" sort="Parkinson, F E" uniqKey="Parkinson F" first="F E" last="Parkinson">F E Parkinson</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1998">1998</date><idno type="RBID">pubmed:10326835</idno><idno type="pmid">10326835</idno><idno type="wicri:Area/PubMed/Corpus">001740</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001740</idno><idno type="wicri:Area/PubMed/Curation">001740</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001740</idno><idno type="wicri:Area/PubMed/Checkpoint">001740</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001740</idno><idno type="wicri:Area/Ncbi/Merge">000019</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effects of propentofylline on adenosine receptor activity in Chinese hamster ovary cell lines transfected with human A1, A2A, or A2B receptors and a luciferase reporter gene.</title><author><name sortKey="Borgland, S L" sort="Borgland, S L" uniqKey="Borgland S" first="S L" last="Borgland">S L Borgland</name><affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacology and Therapeutics, The University of Manitoba, Winnipeg, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology and Therapeutics, The University of Manitoba, Winnipeg</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author><author><name sortKey="Casta N, M" sort="Casta N, M" uniqKey="Casta N M" first="M" last="Casta N">M. Casta N</name></author><author><name sortKey="Spevak, W" sort="Spevak, W" uniqKey="Spevak W" first="W" last="Spevak">W. Spevak</name></author><author><name sortKey="Parkinson, F E" sort="Parkinson, F E" uniqKey="Parkinson F" first="F E" last="Parkinson">F E Parkinson</name></author></analytic><series><title level="j">Canadian journal of physiology and pharmacology</title><idno type="ISSN">0008-4212</idno><imprint><date when="1998" type="published">1998</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine (pharmacology)</term><term>Animals</term><term>CHO Cells</term><term>Colforsin (pharmacology)</term><term>Cricetinae</term><term>Genes, Reporter (drug effects)</term><term>Humans</term><term>Luciferases (biosynthesis)</term><term>Luciferases (drug effects)</term><term>Luciferases (genetics)</term><term>Neuroprotective Agents (pharmacology)</term><term>Purinergic P1 Receptor Antagonists</term><term>Receptor, Adenosine A2A</term><term>Receptor, Adenosine A2B</term><term>Receptors, Purinergic P1 (drug effects)</term><term>Receptors, Purinergic P1 (genetics)</term><term>Transfection</term><term>Xanthines (pharmacology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Luciferases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Luciferases</term><term>Receptors, Purinergic P1</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Luciferases</term><term>Receptors, Purinergic P1</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adenosine</term><term>Colforsin</term><term>Neuroprotective Agents</term><term>Xanthines</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Genes, Reporter</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>CHO Cells</term><term>Cricetinae</term><term>Humans</term><term>Purinergic P1 Receptor Antagonists</term><term>Receptor, Adenosine A2A</term><term>Receptor, Adenosine A2B</term><term>Transfection</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Propentofylline is neuroprotective in vivo, but its mechanism of action is not completely understood. Previously, propentofylline was shown to block adenosine transport processes, to inhibit three adenosine receptor subtypes, and to inhibit cAMP phosphodiesterase. We tested the effect of propentofylline on adenosine receptor function in Chinese hamster ovary (CHO) cells transfected with human adenosine A1, A2A, or A2B receptors and a luciferase reporter gene under control of a promoter sequence containing several copies of the cAMP response element. We investigated the concentration-dependent inhibitory effects of propentofylline on cAMP phosphodiesterase, adenosine transport processes, and adenosine A1, A2A, and A2B receptors. At concentrations > or = 1 mM, propentofylline increased luciferase activity probably as a result of inhibition of cAMP phosphodiesterase. Inhibition of [3H]adenosine uptake by propentofylline was concentration dependent, with IC50 values of 37-39 microM for the three cell types. Agonist-activated adenosine A1 receptors were antagonized by 100 microM propentofylline, but inhibition of agonist-stimulated A2A or A2B receptors was not observed. In contrast, A1 and A2A receptor mediated effects of adenosine were enhanced by propentofylline at concentrations of 1 and 100 microM, respectively. These data indicate that the net effects of propentofylline in vivo will be dependent on the concentrations of propentofylline and adenosine available and on the subtypes of adenosine receptors, phosphodiesterases, and nucleoside transporters present.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10326835</PMID><DateCreated><Year>1999</Year><Month>06</Month><Day>30</Day></DateCreated><DateCompleted><Year>1999</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0008-4212</ISSN><JournalIssue CitedMedium="Print"><Volume>76</Volume><Issue>12</Issue><PubDate><Year>1998</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Canadian journal of physiology and pharmacology</Title><ISOAbbreviation>Can. J. Physiol. Pharmacol.</ISOAbbreviation></Journal><ArticleTitle>Effects of propentofylline on adenosine receptor activity in Chinese hamster ovary cell lines transfected with human A1, A2A, or A2B receptors and a luciferase reporter gene.</ArticleTitle><Pagination><MedlinePgn>1132-8</MedlinePgn></Pagination><Abstract><AbstractText>Propentofylline is neuroprotective in vivo, but its mechanism of action is not completely understood. Previously, propentofylline was shown to block adenosine transport processes, to inhibit three adenosine receptor subtypes, and to inhibit cAMP phosphodiesterase. We tested the effect of propentofylline on adenosine receptor function in Chinese hamster ovary (CHO) cells transfected with human adenosine A1, A2A, or A2B receptors and a luciferase reporter gene under control of a promoter sequence containing several copies of the cAMP response element. We investigated the concentration-dependent inhibitory effects of propentofylline on cAMP phosphodiesterase, adenosine transport processes, and adenosine A1, A2A, and A2B receptors. At concentrations > or = 1 mM, propentofylline increased luciferase activity probably as a result of inhibition of cAMP phosphodiesterase. Inhibition of [3H]adenosine uptake by propentofylline was concentration dependent, with IC50 values of 37-39 microM for the three cell types. Agonist-activated adenosine A1 receptors were antagonized by 100 microM propentofylline, but inhibition of agonist-stimulated A2A or A2B receptors was not observed. In contrast, A1 and A2A receptor mediated effects of adenosine were enhanced by propentofylline at concentrations of 1 and 100 microM, respectively. These data indicate that the net effects of propentofylline in vivo will be dependent on the concentrations of propentofylline and adenosine available and on the subtypes of adenosine receptors, phosphodiesterases, and nucleoside transporters present.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Borgland</LastName><ForeName>S L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics, The University of Manitoba, Winnipeg, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castañón</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Spevak</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Parkinson</LastName><ForeName>F E</ForeName><Initials>FE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Can J Physiol Pharmacol</MedlineTA><NlmUniqueID>0372712</NlmUniqueID><ISSNLinking>0008-4212</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058915">Purinergic P1 Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043705">Receptor, Adenosine A2A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043704">Receptor, Adenosine A2B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018047">Receptors, Purinergic P1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014970">Xanthines</NameOfSubstance></Chemical><Chemical><RegistryNumber>1F7A44V6OU</RegistryNumber><NameOfSubstance UI="D005576">Colforsin</NameOfSubstance></Chemical><Chemical><RegistryNumber>5RTA398U4H</RegistryNumber><NameOfSubstance UI="C032114">propentofylline</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.13.12.-</RegistryNumber><NameOfSubstance UI="D008156">Luciferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>K72T3FS567</RegistryNumber><NameOfSubstance UI="D000241">Adenosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000241" MajorTopicYN="N">Adenosine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005576" MajorTopicYN="N">Colforsin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008156" MajorTopicYN="N">Luciferases</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058915" MajorTopicYN="Y">Purinergic P1 Receptor Antagonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043705" MajorTopicYN="N">Receptor, Adenosine A2A</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043704" MajorTopicYN="N">Receptor, Adenosine A2B</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018047" MajorTopicYN="N">Receptors, Purinergic P1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014970" MajorTopicYN="N">Xanthines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>5</Month><Day>18</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>5</Month><Day>18</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10326835</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country><region><li>Manitoba</li></region><settlement><li>Winnipeg</li></settlement><orgName><li>Université du Manitoba</li></orgName></list><tree><noCountry><name sortKey="Casta N, M" sort="Casta N, M" uniqKey="Casta N M" first="M" last="Casta N">M. Casta N</name><name sortKey="Parkinson, F E" sort="Parkinson, F E" uniqKey="Parkinson F" first="F E" last="Parkinson">F E Parkinson</name><name sortKey="Spevak, W" sort="Spevak, W" uniqKey="Spevak W" first="W" last="Spevak">W. Spevak</name></noCountry><country name="Canada"><region name="Manitoba"><name sortKey="Borgland, S L" sort="Borgland, S L" uniqKey="Borgland S" first="S L" last="Borgland">S L Borgland</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000019 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000019 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:10326835
|texte= Effects of propentofylline on adenosine receptor activity in Chinese hamster ovary cell lines transfected with human A1, A2A, or A2B receptors and a luciferase reporter gene.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:10326835" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |